Histone deacetylase inhibitor SAHA as potential targeted therapy agent for larynx cancer cells

Journal of Cancer

Volumn 8, Issue 1, 2017, Pages 19-28

  Grabarska, Aneta ^a   Luszczki, Jarogniew J ^a,b   Nowosadzka, Ewa ^a   Gumbarewicz, Ewelina ^a   Jeleniewicz, Witold ^a   Dmoszynska Graniczka, Magdalena ^a   Kowalczuk, Krystyna ^a   Kupisz, Krzysztof ^d   Polberg, Krzysztof ^c   Stepulak, Andrzej ^a,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c MSWiA Hospital   (Poland)

^d Jan Bozy District Hospital   (Poland)

Author keywords

Cisplatin (CDDP); Histone deacetylase inhibitors; Isobolography; Larynx cancer; Suberoylanilide hydroxamic acid (SAHA)

Indexed keywords

CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE H3; MESSENGER RNA; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BRDU ASSAY; CCND1 GENE; CDKN1A GENE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; DRUG POTENTIATION; FLOW CYTOMETRY; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; ISOBOLOGRAPHIC ANALYSIS; LARYNGEAL CANCER CELL LINE; LARYNX SQUAMOUS CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MTT ASSAY; NUCLEOSOME; ONCOGENE; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; SKIN FIBROBLAST; SURVIVAL RATE; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING;

EID: 85009767628     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.16655     Document Type: Article

References (61)

1. Baker SJ, Reddy EP. Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med. 2010; 77: 573-86.
2. Peterson C. Drug therapy of cancer. Eur J Clin Pharmacol. 2011; 67: 437-47.
3. Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Leveque D, et al. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies. Eur J Cancer. 2014; 50: 2020-36.
4. Jenckel F, Knecht R. State of the art in the treatment of laryngeal cancer. Anticancer Res. 2013; 33: 4701-10.
5. Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer. 2005; 5: 127-35.
6. Xiang C, Lv Y, Wei Y, Wei J, Miao S, Mao X, et al. Effect of EphA7 Silencing on Proliferation, Invasion and Apoptosis in Human Laryngeal Cancer Cell Lines Hep-2 and AMC-HN-8. Cell Physiol Biochem. 2015; 36: 435-45.
7. Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2016; 91: 386-96.
8. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31: 1869-83.
9. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5: 769-84.
10. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007; 26: 5420-32.
11. Mercurio C, Minucci S, Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res. 2010; 62: 18-34.
12. Zhang J, Zhong Q. Histone deacetylase inhibitors and cell death. Cell Mol Life Sci. 2014; 71: 3885-901.
13. Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015; 20: 3898-941.
14. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014; 124: 30-9.
15. Zwergel C, Valente S, Jacob C, Mai A. Emerging approaches for histone deacetylase inhibitor drug discovery. Expert Opin Drug Discov. 2015; 10: 599-613.
16. Rzeski W, Paduch R, Klatka J, Kandefer-Szerszen M, Stepulak A, Pozarowski P, et al. Establishment and preliminary characterization of two cell lines derived from larynx carcinoma. Folia Histochem Cytobiol. 2002; 40: 195-6.
17. Rzeski W, Stepulak A, Szymanski M, Juszczak M, Grabarska A, Sifringer M, et al. Betulin elicits anti-cancer effects in tumour primary cultures and cell lines in vitro. Basic Clin Pharmacol Toxicol. 2009; 105: 425-32.
18. Jarzab A, Grabarska A, Kielbus M, Jeleniewicz W, Dmoszynska-Graniczka M, Skalicka-Wozniak K, et al. Osthole induces apoptosis, suppresses cell-cycle progression and proliferation of cancer cells. Anticancer Res. 2014; 34: 6473-80.
19. Litchfield JT, Jr., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949; 96: 99-113.
20. Wawruszak A, Luszczki JJ, Grabarska A, Gumbarewicz E, Dmoszynska-Graniczka M, Polberg K, et al. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis. PLoS One. 2015; 10: e0143013.
21. Luszczki JJ. Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application. Naunyn Schmiedebergs Arch Pharmacol. 2007; 375: 105-14.
22. Luszczki JJ, Czuczwar SJ. Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn Schmiedebergs Arch Pharmacol. 2004; 369: 434-46.
23. Luszczki JJ, Czuczwar SJ. Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis. Naunyn Schmiedebergs Arch Pharmacol. 2006; 374: 51-64.
24. Grabovsky Y, Tallarida RJ. Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J Pharmacol Exp Ther. 2004; 310: 981-6.
25. Tallarida RJ. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther. 2006; 319: 1-7.
26. Tallarida RJ. Interactions between drugs and occupied receptors. Pharmacol Ther. 2007; 113: 197-209.
27. Grabarska A, Dmoszynska-Graniczka M, Jeleniewicz W, Kielbus M, Nowosadzka E, Rivero-Muller A, et al. Valproic acid suppresses growth and enhances cisplatin cytotoxicity to larynx cancer cells. Head and Neck Oncology. 2014; 6: 7.
28. Tallarida RJ. Drug Synergism and Dose-Effect Data Analysis: Chapman and Hall/CRC; 2000.
29. Kumar B, Yadav A, Lang JC, Teknos TN, Kumar P. Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells b y t argeting c ancer s tem c ells via t he d ownregulation o f n anog. G enes Cancer. 2015; 6: 169-81.
30. Olson DE, Sleiman SF, Bourassa MW, Wagner FF, Gale JP, Zhang YL, et al. Hydroxamate-based histone deacetylase inhibitors can protect neurons from oxidative stress via a histone deacetylase-independent catalase-like mechanism. Chem Biol. 2015; 22: 439-45.
31. Iwamoto M, Friedman EJ, Sandhu P, Agrawal NG, Rubin EH, Wagner JA. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother Pharmacol. 2013; 72: 493-508.
32. Slingerland M, Guchelaar HJ, Gelderblom H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs. 2014; 25: 140-9.
33. Emanuele S, Lauricella M, Tesoriere G. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). Int J Oncol. 2008; 33: 637-46.
34. Sun PC, Tzao C, Chen BH, Liu CW, Yu CP, Jin JS. Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 a rrest o f 3 20 H SR c olon c ancer c ells. J Biomed Sci. 2010; 17: 76.
35. Butler L M, A gus D B, Scher H I, H iggins B, R ose A , C ordon-Cardo C, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000; 60: 5165-70.
36. Chiaradonna F , B arozzi I , M iccolo C , B ucci G , P alorini R , F ornasari L , e t a l. Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. Antioxid Redox Signal. 2015; 23: 15-29.
37. Komatsu N , K awamata N , T akeuchi S , Yin D , C hien W , M iller C W, e t a l. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep. 2006; 15: 187-91.
38. Xu XD, Yang L, Zheng LY, Pan YY, Cao ZF, Zhang ZQ, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells. BMC Cancer. 2014; 14: 373.
39. Xu J , Sampath D, Lang FF, Prabhu S, Rao G , Fuller GN, et al. V orinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. J Neurooncol. 2011; 105: 241-51.
40. Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Petru E, Zatloukal K, et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer. 2010; 9: 49.
41. Chen S, Zhao Y, Gou WF, Zhao S, Takano Y, Zheng HC. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells. PLoS One. 2013; 8: e79781.
42. Nagumo T, Takaoka S , Y oshiba S , O hashi M , Shirota T, Hatori M, et al. Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo. Oral Oncol. 2009; 45: 766-70.
43. Diyabalanage HV, Granda ML, Hooker JM. Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett. 2013; 329: 1-8.
44. Thurn K T, T homas S , R aha P , Q ureshi I , M unster P N. H istone d eacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther. 2013; 12: 2078-87.
45. Richon VM, Garcia-Vargas J, Hardwick JS. Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 2009; 280: 201-10.
46. Li Z, Zhu WG. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications. Int J Biol Sci. 2014; 10: 757-70.
47. Etchegaray JP, Zhong L, Mostoslavsky R. The histone deacetylase SIRT6: at the crossroads between epigenetics, metabolism and disease. Curr Top Med Chem. 2013; 13: 2991-3000.
48. Cea M, Cagnetta A, Adamia S, Acharya C, Tai YT, Fulciniti M, et al. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016; 127: 1138-50.
49. Gong F, Miller KM. Mammalian DNA repair: HATs and HDACs make their mark through histone acetylation. Mutat Res. 2013; 750: 23-30.
50. Jin KL, Park JY, Noh EJ, Hoe KL, Lee JH, Kim JH, et al. The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells. J Gynecol Oncol. 2010; 21: 262-8.
51. Shen J , H uang C , J iang L , G ao F , Wang Z, Zhang Y, et al. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol. 2007; 73: 1901-9.
52. Suzuki M , E ndo M , S hinohara F , E chigo S , R ikiishi H . E nhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer Chemother Pharmacol. 2009; 64: 1115-22.
53. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003; 63: 7291-300.
54. Giannini G, Cabri W, Fattorusso C, Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med Chem. 2012; 4: 1439-60.
55. Dashwood RH, Myzak MC, Ho E. Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis. 2006; 27: 344-9.
56. He G, Kuang J, Koomen J, Kobayashi R, Khokhar AR, Siddik ZH. Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents. Br J Cancer. 2013; 109: 2378-88.
57. Kwon S H, A hn S H, K im Y K, B ae G U, Y oon J W, H ong S , e t a l. A picidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem. 2002; 277: 2073-80.
58. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene. 1999; 18: 7016-25.
59. Wu X, Yang N, Zhou WH, Xu J, Chen JJ, Zheng FM, et al. Up-regulation of P21 inhibits TRAIL-mediated extrinsic apoptosis, contributing resistance to SAHA in acute myeloid leukemia cells. Cell Physiol Biochem. 2014; 34: 506-18.
60. Kelly W K, O 'Connor O A, K rug L M, C hiao J H, H eaney M , C urley T , e t a l. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005; 23: 3923-31.
61. Valdez BC, Li Y, Murray D, Brammer JE, Liu Y, Hosing C, et al. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget. 2016; ahead of print.